N-Acétyl-D-mannosamine, min 98%, 5 g, emballage plastique.

BENZYL ((5-METHYLAZEPAN-4-YL)METHYL)CARBAMATE, 95.0%, 250mg

4-Bromo-5-chloro-2-fluorobenzenesulfonyl chloride, 97.0%, 10g

(t-Bu)PhCPhos Pd G3, 98.0%, 250mg

2-Methyl-1-heptene>98.0%(GC)5mL

5-(4-Fluorophenyl)valeric acid, 98.0%, 2g

d-Methioninol, 95.0%, 1g

Solution de modificateur de matrice de nitrate de magnésium, 10 g/L Mg(NO3)2 (99,999 %) dans H2O, 50 mL

Phenyl(tetrahydro-2H-pyran-4-yl)methanone, 97%, 250mg

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester, 97.0%, 25g

(2S,4R)-1-Acetyl-4-hydroxypyrrolidine-2-carboxylic acid, 95.0%, 500g

2,2,2-Trifluoro-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2H)-yl)ethanone, 95.0%, 250mg

2-chloro-N-(2,4-dimethoxyphenyl)nicotinamide, 95.0%, 1g